People I (Mostly) Admire 115. The Future of Therapy Is Psychedelic
11 snips
Sep 30, 2023 
Rick Doblin, founder of MAPS, shares his 37-year journey advocating for MDMA-assisted therapy for PTSD. He discusses shifting perceptions of psychedelics from 'recreational' use to therapeutic potential. Doblin explains the intricacies of MDMA therapy, emphasizing its transformative impact on neuroplasticity and mental health. With humor and heart, he also reflects on his unconventional bond with a pet wolf, symbolizing deeper connections and healing. The conversation highlights both the rigorous research behind these therapies and the urgent need for societal change in mental health approaches.
AI Snips
Chapters
Books
Transcript
Episode notes
PTSD Brain Impact
- PTSD affects the brain through a hyperactive amygdala (fear processing) and reduced prefrontal cortex activity (logical thinking).
- This combination leads to heightened threat perception and difficulty processing traumatic memories.
MDMA-Assisted Therapy Success Rate
- MAPS' phase 3 trials for MDMA-assisted therapy showed a 67% remission rate for chronic PTSD after two months.
- An additional 21% experienced significant symptom reduction, resulting in an 88% total response rate.
MDMA's History and Criticism
- Rick Doblin discusses the history of MDMA, its initial use as a therapy drug, and its subsequent criminalization.
- He highlights the irony of criticisms against MAPS for advocating for a drug's approval, rather than a pharmaceutical company.
